Davie, FL, United States of America

Jianbo Xie


Average Co-Inventor Count = 3.6

ph-index = 4

Forward Citations = 232(Granted Patents)


Company Filing History:


Years Active: 1997-2016

Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovations of Jianbo Xie

Introduction

Jianbo Xie is a notable inventor based in Davie, Florida, recognized for his contributions to the field of pharmaceuticals. He holds a total of six patents, showcasing his innovative approach to drug formulation and delivery systems. His work primarily focuses on creating effective oral dosage forms for central nervous system stimulants.

Latest Patents

Among his latest patents is the development of an oral controlled release dosage form. This dosage form is designed to provide a controlled release of a solid formulation for the oral administration of a central nervous system stimulant, specifically methylphenidate hydrochloride. This innovation aims to enhance the therapeutic efficacy and patient compliance in the treatment of attention deficit hyperactivity disorder (ADHD).

Career Highlights

Jianbo Xie has made significant strides in his career at Andrx Pharmaceuticals, Inc. His expertise in pharmaceutical sciences has led to advancements in drug delivery systems, particularly in the area of controlled release formulations. His contributions have been instrumental in improving the quality of life for patients requiring effective medication management.

Collaborations

Throughout his career, Jianbo has collaborated with esteemed colleagues such as Chih-Ming Chen and Manesh Dixit. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas, ultimately leading to the successful development of new pharmaceutical products.

Conclusion

Jianbo Xie's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and collaborations reflect a commitment to improving drug delivery systems, making a significant impact on patient care. His contributions continue to shape the future of pharmaceutical formulations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…